You are here

Lower Infectious Risk Donor Pigs for Xenotransplantation

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: N/A
Agency Tracking Number: 2R44AI048349-02
Amount: $0.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2001
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
BLDG 75, 3RD AVE, NAVY YARD
BOSTON, MA 02129
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 CLIVE PATIENCE
 () -
Business Contact
Phone: (617) 241-5200
Email: JULIA.GREENSTEIN@BIOTRANSPLANT.COM
Research Institution
N/A
Abstract

DESCRIPTION (Adapted from Applicant's Abstract): This is a new, fast track
application that explains the need for additional therapeutics for the
treatment of chronic hepatitis B virus (HBV) infection. Discovery of novel non
cytotoxic L-nucleosides with potent anti-HBV activity that, when used in
combination, act synergistically is described. These L-nucleosides are reported
to inhibit the viral DNA polymerase and replication without effect upon
cellular polymerases or mitocohndrial function and have been shown to
significantly reduce viral load in the chronic woodchuck hepatitis model.
Funding from SBIR phase 1 and 2 will be used to select and develop the
combination of the L-nucleosides with the greatest potential for
commercialization. Phase 1 will determine pharmacology, toxicology and
antiviral potency of two and three L nucleoside combinations in the woodchuck
chronic hepatitis model.

PROPOSED COMMERCIAL APPLICATION:
Chronic treatment of Hepatitis B virus infection. Delay in progression to cirrhosis and
hepatocellular carcinoma. Possible elimination of Hepatitis B virus.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government